



Press release | Lund 2026-06-16

Coegin Pharma receives highly encouraging user feedback from Hårklinikken

Coegin Pharma AB (“Coegin” or the “Company”) today announces receiving highly encouraging feedback from Hårklinikken, a leading provider of science-led hair and scalp treatments worldwide, following a 16-week customer panel evaluation conducted at one of the Hårklinikken clinics. The evaluation focused on customer satisfaction following daily use of Follicopeptide® Gel Serum alongside a special made Hårklinikken serum. The positive feedback reported by Hårklinikken is consistent with the results generated during the clinical development of Follicopeptide® and with the encouraging consumer experiences reported from other commercial evaluations and market introductions. The evaluation further supports a planned broader commercial launch in the second half of 2026.

The purpose of the evaluation was to explore the potential of a combination approach designed to optimize the customer experience and support Hårklinikken’s ambition to offer a premium treatment concept built around complementary technologies.

Participants using Follicopeptide® Gel Serum in combination with the special made Hårklinikken serum reported reduced hair shedding, higher hair density, and the perception of thicker, fuller-looking hair. According to Hårklinikken, the evaluation demonstrated a high level of customer satisfaction, with many participants reporting noticeable improvements as early as within the first 8 weeks of daily use.

The encouraging results support ongoing preparations for a broader commercial roll-out of Follicopeptide® Gel Serum under Hårklinikken’s own brand across the company’s physical clinics in US, Europe and Middle East, and online sales channels in the second half of 2026.

The positive feedback from Hårklinikken aligns well with findings from Follicopeptide®’s extensive clinical development program and the encouraging feedback Coegin has received from distributors, clinics and consumers following commercial launches. Together, these observations further support the commercial potential of Follicopeptide®.

“We are very pleased to see this level of customer satisfaction from a respected professional player such as Hårklinikken,” says Jens Eriksson, CEO of Coegin Pharma. “The feedback reinforces our confidence in the commercial potential of Follicopeptide® and further validates the growing interest we are seeing from our clients and partners internationally. Hårklinikken has built a strong reputation

Coegin Pharma AB

c/o Medicon Village


223 81 Lund, Sweden

Registration number

559078-0465

coeginpharma.com

info@coeginpharma.com





worldwide over three decades, and their decision to expand the collaboration represents an important commercial milestone for Coegin.”

Lars Skjøth, Founder and CEO of Hårklinikken, comments:

“These results give us strong confidence in the combination approach. Based on this evaluation, we see a solid foundation for a broader collaboration with Coegin Pharma and we’re preparing for a larger launch of Follicopeptide® Gel Serum under our own brand across our clinics and online channels during the second half of 2026”.

The planned expansion reflects Hårklinikken’s confidence in the commercial opportunity surrounding Follicopeptide® and supports Coegin’s strategy of partnering with leading professional operators to accelerate global market adoption.

For further information, please contact:

Jens Eriksson, CEO, or Lars B. Rasmussen, CFO

Email: info@coeginpharma.com

About Coegin Pharma

Coegin Pharma is a Swedish innovation company developing and commercializing advanced cosmetic technologies for hair and skin. The company’s flagship innovation, Follicopeptide, is a patented, clinically developed peptide technology targeting hair thinning. It is currently being introduced globally through selected partners and the company’s own brand platform. In parallel, Coegin is also developing NPP-4, a next-generation cosmetic peptide innovation designed to enhance skin tone without UV exposure or chemicals.

With scalable in-house production, established intellectual property, and a flexible commercial model, Coegin Pharma is positioned to bring differentiated, science-based products to the global cosmetics market.

Coegin Pharma’s share is listed on the NGM Growth Market and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

For more information, including company updates and social media links, visit coeginpharma.com

About Hårklinikken

Hårklinikken is a Danish science-led company dedicated to hair and scalp health. With over 33 years of scientific research, product development and clinical experience in Europe, US, and the Middle East, they are considered the leading company on the intricate complexities concerning hair loss and hair thinning in men and women, and how it varies amongst different ethnic groups around the world.

The work has been led by founder and head of R&D Lars Skjøth as well Dr. Panos Vasiloudes, a board-certified dermatologist and PhD.

The products that Hårklinikken offers are customized treatment methods based on botanical metabolites, clinically tested ingredients, along with advanced technology and expertise to deliver outstanding results.

Coegin Pharma AB

c/o Medicon Village

223 81 Lund, Sweden

Registration number

559078-0465

coeginpharma.com

info@coeginpharma.com





Hårkliniken has offered online consultations worldwide for the past 20 years and has flagship clinics in Dubai, Beverly Hills, New York City, Reykjavik, Copenhagen and Aarhus proving its global reach and prestige. Known for modern design, expert teams, and world-class service, Hårkliniken is a trusted partner for clients seeking proven, science-led, individualized solutions for healthier hair.

More information is available at www.harkliniken.com

Coegin Pharma AB

c/o Medicon Village

223 81 Lund, Sweden

Registration number

559078-0465

coeginpharma.com

info@coeginpharma.com